Last reviewed · How we verify
NCT04333511
Brain Stimulation for Patients With Parkinson Disease
NA trial testing TPS (NEUROLITH) in Parkinson Disease in 30 participants. Completed in 3 August 2022.
3 August 2022
Quick facts
| Lead sponsor | Storz Medical AG |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 2 December 2019 |
| Primary completion | 3 August 2022 |
| Estimated completion | 3 August 2022 |
| Sites | 1 location across Austria |
Drugs / interventions tested
- TPS (NEUROLITH)
- Sham-TPS (NEUROLITH)
Conditions studied
- Parkinson Disease — all drugs for Parkinson Disease →
Sponsor
Storz Medical AG — full company profile →
Who can join
18 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this crossover study is to investigate the efficacy of non-invasive brain stimulation (transcranial pulse stimulation; TPS) in adults with Parkinson Disease (PD). Participants will receive 6 sessions of TPS and Sham-TPS, respectively, in random order. Motor manifestations of PD and manual dexterity will be the primary outcome measures. Outcomes will be assessed immediately post-treatment.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Current state of clinical ultrasound neuromodulation.
Matt E, Radjenovic S, Mitterwallner M, Beisteiner R. · · 2024 · cited 27× · PMID 38962179 · DOI 10.3389/fnins.2024.1420255 -
Transcranial Pulse Stimulation Enhances Dexterity in Parkinson’s Disease: A Randomized Sham-Controlled Clinical Trial
Matt E, Plischek N, Mitterwallner M, Radjenovic S, et al · · 2025 · DOI 10.1101/2025.07.07.25330807
Verify or expand the search:
- PubMed search for NCT04333511
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
- NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
- NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
- NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting
Other Storz Medical AG trials
Trials by the same sponsor.
- NCT03438500 — Cardiac Shock Wave Treatment in Patients With Reduced Coronary Flow Reserve · NA · withdrawn
- NCT03770182 — Brain Stimulation for Neurological Patients · NA · completed
- NCT04333329 — Transcranial Pulse Stimulation (TPS) for Alzheimer's Disease (AD) · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04333511 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Storz Medical AG
- Last refreshed: 3 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04333511.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing